Welcome to Arrayit
Bringing microarrays to the market
Arrayit customers include the brightest minds in university laboratories, government laboratories, biotechnology companies, life sciences companies, clinical laboratories, pharmaceutical companies and hospitals worldwide. Arrayit microarray technology empowers scientists with the tools required to make important discoveries and change the world.
Arrayit Life Sciences Suite
Arrayit offers a full suite of microarray-based products and services to empower researchers with the tools required to make next generation discoveries for human kind.
Microarrays are miniaturized testing devices that enable researchers to measure gene expression levels, detect variants in gene sequences, quantify antibody levels in the bloodstream and miniaturize a vast number of laboratory procedures currently being performed on a macro-scale. Miniaturization leverages glass slides, fluorescence, robotics and computer automation to greatly accelerate data acquisition. Arrayit’s unique contact printing technology permits researchers to manufacture microarrays of every living organism.
Advances in Breast Cancer Research
An Autoantibody Based Protein Microarray Blood Test to Enhance the Specificity of a Negative Screening MammogramRead Publication
Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis
Purpose. Nonmuscle invasive bladder cancer (BCa) has a high recurrence rate requiring lifelong surveillance. Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of recurrent bladder cancer. However, no single marker can achieve the required accuracy. The purpose of this study was to select a multiparameter panel, comprising urinary biomarkers and clinical parameters, for BCa recurrence diagnosis. Experimental Design. Candidate biomarkers were measured in urine samples of BCa patients with recurrence and BCa patients without recurrence. A multiplatform strategy was used for marker quantification comprising a multiplexed microarray and an automated platform for ELISA analysis. A multivariate statistical analysis combined the results fromboth platforms with the collected clinical data. Results.Thebest performing combination of biomarkers and clinical parameters achieved an AUC value of 0.91, showing better performance than individual parameters. This panel comprises six biomarkers (cadherin-1, IL-8, ErbB2, IL-6, EN2, and VEGF-A) and three clinical parameters (number of past recurrences, number of BCG therapies, and stage at time of diagnosis). Conclusions. The multiparameter panel could be a useful noninvasive tool for BCa surveillance and potentially impact the clinical management of this disease. Validation of results in an independent cohort is warranted.Read Publication
Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays
Abstract A noninvasive screening test would significantly facilitate early detection of epithelial ovarian cancer. This study used a combination of high-throughput selection and arraybased serologic detection of many antigens indicative of the presence of cancer, thereby using the immune system as a biosensor. This high-throughput selection involved biopanning of an ovarian cancer phage display library using serum immunoglobulins from an ovarian cancer patient as bait. Protein macroarrays containing 480 of these selected antigen clones revealed 65 clones that interacted with immunoglobulins in sera from 32 ovarian cancer patients but not with sera from 25 healthy women or 14 patients having other benign or malignant gynecologic diseases. Sequence analysis data of these 65 clones revealed 62 different antigens. Among the markers, we identified some known antigens, including RCAS1, signal recognition protein- 19, AHNAK-related sequence, nuclear autoantogenic sperm protein, Nijmegen breakage syndrome 1 (Nibrin)...Read Publication
Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies
Abstract: New minimal invasive diagnostic methods for early detection of lung cancer are urgently needed. It is known that the immune system responds to tumors with production of tumor-autoantibodies. Protein microarrays are a suitable highly multiplexed platform for identification of autoantibody signatures against tumor-associated antigens (TAA). These microarrays can be probed using 0.1 mg immunoglobulin G (IgG), purified from 10 μL of plasma. We used a microarray comprising recombinant proteins derived from 15,417 cDNA clones for the screening of 100 lung cancer samples, including 25 samples of each main histological entity of lung cancer, and 100 controls. Since this number of samples cannot be processed at once, the resulting data showed...Read Publication
Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence
Abstract. Ovarian cancer (OVCA) has a high incidence of recurrence and a high rate of mortality. We performed a pilot study to evaluate the usefulness of tumor autoantibodies to tumor associated antigens (TAA) to predict OVCA recurrence. A validation study with 56 antigens, previously identified in the initial phase of the study, along with 13 known tumor antigens on protein arrays was performed on an independent cohort of recurrent and non-recurrent OVCA patients. Statistical analyses revealed that a panel of 3 antigens predicted recurrence at a median time of 9.07 months prior to clinical recurrence in a study population, where majority of patients had CA125 values less than 35 U/ml, with an average...Read Publication
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
A high-capacity system was developed to monitor the expression of many genes in parallel. Microarrays prepared by high-speed robotic printing of complementary DNAs on glass were used for quantitative expression measurements of the corresponding genes. Because of the small format and high density of the arrays, hybridization volumes of 2 microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA. Differential expression measurements of 45 Arabidopsis genes were made by means of simultaneous, two-color fluorescence hybridization.Read Publication
Arrayit® leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe. Arrayit is publicly traded, the ticker symbol is ARYC.Read Publication
The First Array article from the Scientist
Ron Davis and I were studying plant transcription factors in 1990, but progress was slow and arduous because the gene expression tools were so primitive. We conceived of the DNA microarrayin 1993 to speed up gene expression analysis....Read Publication
IC 001. US 001 005 006 010 026 046. G & S: Diagnostic preparations for scientific or research use; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific use; Diagnostic preparations used in science; ...Read Publication
GEN Magazine Article: Microarray Not Fade Away
Yes, many are attracted to next-generation sequencing, but loyalty to chip-based phenotyping has its rewards, particularly in screens of large sample sets.
The microarray, the legacy technology for measuring gene expression, will not go gentle into that good night. True, in some respects, the microarray will be eclipsed by nextgeneration sequencing (NGS), specifically, whole transcriptome shotgun sequencing. But the microarray will remain indispensible for many applications. Beyond that, the microarray will evolve to complement NGS applications, finding reasons to stay relevant besides the loyalty of its long-time users.Read Publication
Accurate, Rapid, Cost-Effective Blood Test Aims to Confirm True Negative Findings While Halving the Rate of False Negative Mammography Results—...Read Publication
U.S. Patent for Microarray printing device
The invention herein describes a device for fabricating microarrays of biochemical substances, consisting of a holder and one or more printing pins. ...Read Publication
U.S.Patent on Neoepitope detection of desease using protein arrays
A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indictative of a specific desease. ...Read Publication
Biomarkers in Cancer article from Libertas Academica
ABSTRACT: In order to develop a new tool for diagnosis of breast cancer based on utoantibodies against a panel of biomarkers, a clinical trial including blood samples from 507 subjects was conducted. All subjects showed a breast abnormality on exam or breast imaging and final biopsy pathology of either breast cancer patients or healthy controls.
About our Company
Arrayit provides microarray tools to brilliant life sciences researchers worldwide to empower discoveries in biomedicine and agriculture. New clinical tests, safer medicines, better crop plants and breathtaking insights into human disease are among the many possibilities afforded by Arrayit microarray technology.
Publication of the Month
Metoboroghene O. Mowoe and colleagues from the Department of Integrative Biomedical Sciences at the University of Cape Town in South Africa published a preprint entitled “Reaching the Remote: Dried Blood Spot Analysis for Disease Diagnosis on a Protein Microarray Platform” in which Arrayit blood cards are used to explore the feasibility of remote pancreatic cancer screening using a few drops of blood.